Response by Pennlert et al to Letter Regarding Article, "Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation". - Suppr | 超能文献

Response by Pennlert et al to Letter Regarding Article, "Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation".

作者信息

Pennlert Johanna, Asplund Kjell, Eriksson Marie

机构信息

Department of Public Health and Clinical Medicine, Medicine, Umeå University, Sweden.

Department of Statistics, Umeå School of Business and Economics, Umeå University, Sweden.

出版信息

Stroke. 2017 Apr;48(4):e116. doi: 10.1161/STROKEAHA.117.016838. Epub 2017 Mar 10.

DOI:10.1161/STROKEAHA.117.016838

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Response by Pennlert et al to Letter Regarding Article, "Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation".

Stroke. 2017 Apr;48(4):e116. doi: 10.1161/STROKEAHA.117.016838. Epub 2017 Mar 10.

2

Letter by Nielsen and Johnsen Regarding Article, "Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation".

Stroke. 2017 Apr;48(4):e115. doi: 10.1161/STROKEAHA.117.016747. Epub 2017 Mar 10.

3

In patients with intracerebral haemorrhage and concomitant atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7-8 weeks after ICH.

Evid Based Med. 2017 Jun;22(3):108-109. doi: 10.1136/ebmed-2017-110675. Epub 2017 May 16.

4

Letter by Spiegel et al regarding article, "net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study".

Circulation. 2012 Nov 13;126(20):e322; author reply e323. doi: 10.1161/CIRCULATIONAHA.112.119727.

5

Atrial fibrillation patients who sustained warfarin-associated intracerebral haemorrhage have poor neurological outcomes: results from a matched case series.

Hong Kong Med J. 2017 Apr;23(2):117-21. doi: 10.12809/hkmj164953. Epub 2017 Feb 24.

6

Letter by Reynolds et al regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".

Circulation. 2012 Jan 24;125(3):e291; author reply e293-4. doi: 10.1161/CIRCULATIONAHA.111.056077.

7

Protocol for Cerebral Microbleeds during the Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients with Nonvalvular Atrial Fibrillation (CMB-NOW) Study: Multisite Pilot Trial.

J Stroke Cerebrovasc Dis. 2015 Sep;24(9):2143-8. doi: 10.1016/j.jstrokecerebrovasdis.2015.05.032. Epub 2015 Jul 4.

8

Letter regarding article by Hylek et al, "Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation".

Circulation. 2007 Nov 13;116(20):e538. doi: 10.1161/CIRCULATIONAHA.107.727255.

9

Nationwide survey of neuro-specialists' opinions on anticoagulant therapy after intracerebral hemorrhage in patients with atrial fibrillation.

J Neurol Sci. 2012 Jan 15;312(1-2):82-5. doi: 10.1016/j.jns.2011.08.017. Epub 2011 Aug 27.

10

Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.

Int J Stroke. 2016 Jul;11(5):565-74. doi: 10.1177/1747493016632239. Epub 2016 Feb 29.